Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Fishfa Biogenics: Renowned Manufacturer, & Exporter of Tacrolimus & Mupirocin API.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Tildrakizumab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 303Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Almirall Advances Skin Science at EADV 2025 for Holistic Care
    Almirall Advances Skin Science at EADV 2025 for Holistic Care

    17 Sep 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-09-17/eadv-2025-almirall-advances-skin-science-and-leads-innovation-for-holistic-patient-care-in-medical-dermatology

    PHARMAWEB
    17 Sep 2025
    Share Share
    Sun Pharma’s phase 3 clinical studies evaluating ILUMYA
    Sun Pharma’s phase 3 clinical studies evaluating ILUMYA

    21 Jul 2025

    // EXPRESSPHARMA

    https://www.expresspharma.in/sun-pharmas-phase-3-clinical-studies-evaluating-ilumya-in-active-psoriatic-arthritis-met-their-primary-endpoint/

    EXPRESSPHARMA
    21 Jul 2025
    Share Share
    Ilumya Effective In Moderate-To-Severe Nail Psoriasis At AAD 2025
    Ilumya Effective In Moderate-To-Severe Nail Psoriasis At AAD 2025

    07 Mar 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ilumya-tildrakizumab-asmn-found-effective-for-treatment-of-moderate-to-severe-plaque-psoriasis-affecting-nails-in-study-presented-at-2025-aad-conference-302395300.html

    PR NEWSWIRE
    07 Mar 2025
    Share Share
    Almirall To Present New Psoriasis Atopic Dermatitis Data
    Almirall To Present New Psoriasis Atopic Dermatitis Data

    23 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240923201861/en

    BUSINESSWIRE
    23 Sep 2024
    Share Share
    Sun Pharma's Ilumya (Tildrakizumab asmn) Receives Suppl Approval in the U.S.
    Sun Pharma's Ilumya (Tildrakizumab asmn) Receives Suppl Approval in the U.S.

    04 Apr 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761067

    FDA
    04 Apr 2024
    Share Share
    Sun Pharma specialty drug Tildrakizumab makes it to China's reimbursement list
    Sun Pharma specialty drug Tildrakizumab makes it to China's reimbursement list

    13 Dec 2023

    // ECONOMIC TIMES

    https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/sun-pharma-specialty-drug-tildrakizumab-makes-it-to-chinas-reimbursement-list/articleshow/105967100.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst

    ECONOMIC TIMES
    13 Dec 2023
    Share Share